Promising combo targets tough leukemia

This study tests a new way to treat a fast-growing blood cancer called BCR-ABL positive B-cell acute lymphoblastic leukemia. About 80 adults will receive two drugs: ponatinib pills and blinatumomab injections under the skin. The goal is to see if this combination can control the cancer and reduce side effects. Participants will need to take ponatinib for 5 years, so this is a disease-control approach, not a cure.